Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs

Fiser's up to10 billion dollar deal to buy MSA ended a fierce bidding war with Nova Nordisk. It's a move aimed at establishing Fizer in the very fast growing market for obesity drugs. Joining us now any first on CNBC interview to discuss the deal and who knows what else of course is company's chairman and CEO Albert Borla.Nice to have you here. >> Thank you for having me David. >> Um from your original deal to where you ended up I think you're paying another two $2.1% billion.Why was it worth it to you to s ...